心脏收缩力调节器用于心力衰竭的机制和临床研究
Mechanism and clinical study of cardiac contractility modulation for heart failure
卢群 1梁潇 1白玲 1朱丹军 1薛小临 1韩克1
作者信息
- 1. 西安交通大学第一附属医院心血管内科,陕西西安 710061
- 折叠
摘要
心脏收缩力调节器(CCM)作为救治慢性射血分数降低的心力衰竭(HFrEF)的新型植入性电子治疗装置,因可增强心室肌收缩力、改善患者症状体征和心功能指标甚至远期预后,己迅速成为心血管领域倍受关注的热点.本文综述了CCM治疗HFrEF的机制和临床研究,并根据其机制和信号传递算法对其在射血分数保留的心力衰竭(HFpEF)、心脏再同步化治疗(CRT)反应不佳、合并心房颤动的HFrEF患者中的疗效进一步分析和展望,以期推动CCM可以满足更多、不同临床情况的心力衰竭患者的需求.
Abstract
Cardiac contractility modulation(CCM),as a new implantable electronic therapy device for treating chronic heart failure with reduced ejection fraction(HFrEF),has rapidly become a hot topic in the cardiovascular field due to its ability to enhance ventricular myocardial contractility,improve patients'symptoms and signs,cardiac function indexes and even long-term prognosis.This article reviews the mechanism and clinical studies of CCM in treating HFrEF,and based on its mechanism and signal transduction algorithm,further analyzes and prospects its efficacy in patients with heart failure with preserved ejection fraction,cardiac resynchronization therapy non-response,and HFrEF with concomitant atrial fibrillation,aiming to promote CCM to meet the needs of more diverse clinical situations in heart failure patients.
关键词
心脏收缩力调节器/射血分数降低的心力衰竭/机制研究/临床研究Key words
Cardiac contractility modulation/Heart failure with reduced ejection fraction/Mechanism studies/Clinical research引用本文复制引用
基金项目
陕西省科技惠民计划(2016HM-04)
陕西省重点研发计划(2020GXLH-Y-015)
国家自然科学基金(8210021403)
出版年
2024
NETL
NSTL
万方数据